[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641666":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":87,"centralContacts":91,"locations":97,"responsibleParty":208,"collaborators":42,"id":210,"slug":211,"hasResults":212,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":42,"eligibilityCriteria":216,"healthyVolunteers":212,"sex":217,"minAge":218,"maxAge":42,"enrollmentInfo":219,"targetDuration":42,"studyType":222,"phases":223,"briefSummary":226,"conditions":227,"keywords":42,"overallStatus":100,"whyStopped":42,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: MK-1045 plus Rituximab (or biosimilar)","EXPERIMENTAL","Participants will receive escalating doses of MK-1045 (from 2 mg to 90 mg) once weekly (QW) for up to approximately 12 months. Participants will also receive 375 mg\u002Fm\\^2 rituximab (or biosimilar) once every 4 weeks (Q4W) for up to approximately 6 months.",[13,14,15],"Biological: MK-1045","Biological: Rituximab","Biological: Rituximab biosimilar",{"label":17,"type":10,"description":18,"interventionNames":19},"Part 2: MK-1045 plus Rituximab (or biosimilar)","Participants will receive MK-1045 QW at the dose determined in Part 1 for up to approximately 12 months. Participants will also receive 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q4W for up to approximately 6 months.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"Part 2: Physician's Choice of Chemotherapy plus Rituximab (or biosimilar)","Participants will receive physician's choice of: 90 mg\u002Fm\\^2 bendamustine on Days 1 and 2 of each 4-week cycle for up to 6 cycles (up to approximately 6 months) plus 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q4W for up to approximately 6 months OR 750 mg\u002Fm\\^2 cyclophosphamide, 50 mg\u002Fm\\^2 doxorubicin, and 1.4 mg\u002Fm\\^2 vincristine on day 1 of each 3-week cycle (Q3W) and 100 mg\u002Fm\\^2 prednisone (or prednisolone) once daily on days 1 through 5 Q3W for up to 6 cycles (up to approximately 4 months) plus 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q3W for up to approximately 4 months OR 750 mg\u002Fm\\^2 cyclophosphamide and 1.4 mg\u002Fm\\^2 vincristine Q3W and 40 mg\u002Fday prednisone (or prednisolone) once daily on days 1 through 5 of each 3-week cycle for up to 6 cycles (up to approximately 4 months) plus 375 mg\u002Fm\\^2 rituximab (or biosimilar) Q3W for up to approximately 6 months.",[14,15,24,25,26,27,28,29],"Drug: Bendamustine","Drug: Cyclophosphamide","Drug: Vincristine","Drug: Prednisone","Drug: Prednisolone","Drug: Doxorubicin Hydrochloride",[31,38,43,50,58,65,71,77,82],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"BIOLOGICAL","MK-1045","Intravenous (IV) infusion",[9,17],[37],"CN201",{"type":32,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Rituximab","IV infusion",[9,17,21],null,{"type":32,"name":44,"description":40,"armGroupLabels":45,"otherNames":46},"Rituximab biosimilar",[9,17,21],[47,48,49],"TRUXIMA®","RUXIENCE®","RIABNI®",{"type":51,"name":52,"description":40,"armGroupLabels":53,"otherNames":54},"DRUG","Bendamustine",[21],[55,56,57],"Bendeka","Treanda","Belrapzo",{"type":51,"name":59,"description":40,"armGroupLabels":60,"otherNames":61},"Cyclophosphamide",[21],[62,63,64],"Cytoxan","Neosar","Cytophosphane",{"type":51,"name":66,"description":40,"armGroupLabels":67,"otherNames":68},"Vincristine",[21],[69,70],"Oncovin","Vincasar PFS",{"type":51,"name":72,"description":73,"armGroupLabels":74,"otherNames":75},"Prednisone","Per approved product label",[21],[76],"Prednisone acetate",{"type":51,"name":78,"description":73,"armGroupLabels":79,"otherNames":80},"Prednisolone",[21],[81],"Prednisolone acetate",{"type":51,"name":83,"description":40,"armGroupLabels":84,"otherNames":85},"Doxorubicin Hydrochloride",[21],[86],"Adriamycin",[88],{"name":89,"affiliation":5,"role":90},"Medical Director","STUDY_DIRECTOR",[92],{"name":93,"role":94,"phone":95,"phoneExt":42,"email":96},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[98,116,130,142,157,169,181,195],{"facility":99,"status":100,"city":101,"state":102,"zip":103,"country":104,"countryCode":105,"cosmosGeoPoint":106,"geoPoint":111,"contacts":112},"SCRI Oncology Partners ( Site 7000)","RECRUITING","Nashville","Tennessee","37203","United States","US",{"type":107,"coordinates":108},"Point",[109,110],-86.78444,36.16589,{"lat":110,"lon":109},[113],{"name":114,"role":94,"phone":115,"phoneExt":42,"email":42},"Study Coordinator","844-482-4812",{"facility":117,"status":100,"city":118,"state":42,"zip":119,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Hadassah Medical Center ( Site 0701)","Jerusalem","9112001","Israel","IL",{"type":107,"coordinates":123},[124,125],35.21633,31.76904,{"lat":125,"lon":124},[128],{"name":114,"role":94,"phone":129,"phoneExt":42,"email":42},"+97226777333",{"facility":131,"status":100,"city":132,"state":42,"zip":133,"country":120,"countryCode":121,"cosmosGeoPoint":134,"geoPoint":138,"contacts":139},"Sheba Medical Center ( Site 0702)","Ramat Gan","5265601",{"type":107,"coordinates":135},[136,137],34.81065,32.08227,{"lat":137,"lon":136},[140],{"name":114,"role":94,"phone":141,"phoneExt":42,"email":42},"+97235303030",{"facility":143,"status":100,"city":144,"state":145,"zip":146,"country":147,"countryCode":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Hospital Virgen de la Victoria ( Site 0905)","Málaga","Malaga","29010","Spain","ES",{"type":107,"coordinates":150},[151,152],-4.42034,36.72016,{"lat":152,"lon":151},[155],{"name":114,"role":94,"phone":156,"phoneExt":42,"email":42},"34 923291100,56621",{"facility":158,"status":100,"city":159,"state":42,"zip":160,"country":147,"countryCode":148,"cosmosGeoPoint":161,"geoPoint":165,"contacts":166},"Hospital Universitari Vall de Hebron ( Site 0903)","Barcelona","08035",{"type":107,"coordinates":162},[163,164],2.15899,41.38879,{"lat":164,"lon":163},[167],{"name":114,"role":94,"phone":168,"phoneExt":42,"email":42},"+34932746000, 2347",{"facility":170,"status":100,"city":171,"state":42,"zip":172,"country":147,"countryCode":148,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"Hospital Universitario Gregorio Maranon ( Site 0902)","Madrid","28007",{"type":107,"coordinates":174},[175,176],-3.70256,40.4165,{"lat":176,"lon":175},[179],{"name":114,"role":94,"phone":180,"phoneExt":42,"email":42},"34 915868888",{"facility":182,"status":100,"city":183,"state":42,"zip":184,"country":185,"countryCode":186,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Chang Gung Medical Foundation-Linkou Branch ( Site 1002)","Taoyuan","333","Taiwan","TW",{"type":107,"coordinates":188},[189,190],121.29696,24.99368,{"lat":190,"lon":189},[193],{"name":114,"role":94,"phone":194,"phoneExt":42,"email":42},"03-3281200",{"facility":196,"status":100,"city":197,"state":42,"zip":198,"country":199,"countryCode":42,"cosmosGeoPoint":200,"geoPoint":204,"contacts":205},"Hacettepe Universite Hastaneleri ( Site 1110)","Ankara","06230","Turkey (Türkiye)",{"type":107,"coordinates":201},[202,203],32.85427,39.91987,{"lat":203,"lon":202},[206],{"name":114,"role":94,"phone":207,"phoneExt":42,"email":42},"+905348719633",{"type":209,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100641666","phase-2-a-clinical-trial-of-mk-1045-and-rituximab-in-people-with-follicular-lymphoma-mk-1045-007-100641666",false,"NCT07634471","A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)","A Phase 2\u002F3 Randomized, Open-label Study of MK-1045 in Combination With Rituximab in Participants With 1L Follicular Lymphoma","Inclusion Criteria:\n\n* Has biopsy-proven, previously untreated, histologically confirmed cluster of differentiation (CD)19-positive and CD20-positive classical follicular lymphoma (FL), with Ann Arbor Stage II-IV disease and a Follicular Lymphoma International Prognostic Index (FLIPI) score of 2-5.\n* Has radiographically measurable disease per the Lugano Response Criteria.\n* Has provided a newly obtained core or excisional biopsy or archival tissue of a tumor lesion not previously irradiated.\n* If human immunodeficiency virus (HIV)-positive, has well-controlled HIV on antiretroviral therapy (ART).\n* If hepatitis B surface antigen (HBsAg)-positive, has undetectable hepatitis B virus (HBV) viral load and has received HBV antiviral therapy for at least 4 weeks and will continue it.\n* If history of hepatitis C virus (HCV) infection, has undetectable HCV viral load.\n\nExclusion Criteria:\n\n* Has received prior systemic anticancer therapy or radiotherapy for FL.\n* Has follicular large B-cell lymphoma or any other subtype of FL other than classical FL.\n* Has FL that has transformed into a more aggressive type of lymphoma.\n* History or presence of clinically relevant central nervous system (CNS) diseases.\n* Has history of serious cardiovascular and cerebrovascular diseases.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Has known active CNS lymphoma or involvement.\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has chronic liver disease, including liver cirrhosis of Child-Pugh class B or C.\n* Has not adequately recovered from major surgery or has ongoing surgical complications.","ALL","18 Years",{"count":220,"type":221},960,"ESTIMATED","INTERVENTIONAL",[224,225],"PHASE2","PHASE3","Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy.\n\nThe goals of this study are to learn:\n\n* About the safety of MK-1045 and rituximab, and if people tolerate them when given together\n* If people who receive MK-1045 and rituximab have the cancer go away\n* If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)",[228],"Follicular Lymphoma","2026-07-01",{"date":231,"type":232},"2026-07-02","ACTUAL",{"date":234,"type":221},"2026-07-06",{"date":236,"type":221},"2035-07-23",{"name":5,"class":6},8]